SCHEMBL24704131

SCHEMBL24704131

Clc1cc2nc3c(nc2cc1Cl)-c1ccccc1C3

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.53
KDM4E B2RXH2 5/20 0.53
ALDH1A1 P00352 5/20 0.53
PKM P14618 4/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
RAB9A P51151 2/20 0.53
POLB P06746 1/20 0.53
GAA P10253 1/20 0.53
TP53 P04637 3/20 0.50
CYP3A4 P08684 3/20 0.50
CYP2D6 P10635 3/20 0.50
CYP2C9 P11712 3/20 0.50
TSHR P16473 3/20 0.50
MAPK1 P28482 3/20 0.50
CYP2C19 P33261 3/20 0.50
HSD17B10 Q99714 3/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
NPC1 O15118 1/20 0.50
ACHE P22303 9/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31501264 0.86 ACHE (0.57) MAPTKDM4EALDH1A1PKMSMN1; SMN2
SCHEMBL4071777 0.84 MAPT (0.65) MAPTKDM4EALDH1A1PKMSMN1; SMN2
SCHEMBL24704424 0.83 KDM4E (0.60) MAPTKDM4EALDH1A1PKMSMN1; SMN2
SCHEMBL5799814 0.80 METAP2 (0.59) MAPTKDM4EALDH1A1PKMSMN1; SMN2
SCHEMBL31501268 0.80 SMN1; SMN2 (0.52) MAPTKDM4EALDH1A1PKMSMN1; SMN2
SCHEMBL27404178 0.75 KDM4E (0.50) MAPTKDM4EALDH1A1PKMSMN1; SMN2
SCHEMBL31501263 0.74 CYP1A2 (0.61) MAPTKDM4EALDH1A1PKMSMN1; SMN2
SCHEMBL22481864 0.70 MAPT (0.69) MAPTKDM4EALDH1A1PKMSMN1; SMN2
SCHEMBL31284699 0.69 ACHE (0.48) MAPTKDM4EALDH1A1PKMSMN1; SMN2
SCHEMBL31283817 0.69 ACHE (0.45) MAPTKDM4EALDH1A1PKMSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265058-A1 CARBOXYLIC ACID OR CARBOXYLIC ACID ESTER COMPOUND HAVING FUSED-RING STRUCTURE, METHOD FOR PRODUCING THE SAME, AND USE OF COMPOUND FUJIFILM CORPORATION (JP) 2023-08-24 US disclosed
US-20230265058-A1 CARBOXYLIC ACID OR CARBOXYLIC ACID ESTER COMPOUND HAVING FUSED-RING STRUCTURE, METHOD FOR PRODUCING THE SAME, AND USE OF COMPOUND FUJIFILM CORPORATION (JP) 2023-08-24 US disclosed
US-20230183406-A1 COMPOUND, CURABLE RESIN COMPOSITION, CURED PRODUCT, OPTICAL MEMBER, AND LENS FUJIFILM CORPORATION (JP) 2023-06-15 US disclosed
US-20230183406-A1 COMPOUND, CURABLE RESIN COMPOSITION, CURED PRODUCT, OPTICAL MEMBER, AND LENS FUJIFILM CORPORATION (JP) 2023-06-15 US disclosed
WO-2022255228-A1 COMPOSITION, CURED PRODUCT OR COMPACT, OPTICAL MEMBER, AND LENS 富士フイルム株式会社 2022-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183406-A1 COMPOUND, CURABLE RESIN COMPOSITION, CURED PRODUCT, OPTICAL MEMBER, AND LENS POLR1A, RAD51, POLR2A MAPT 419/4885KDM4E 2324/4885ALDH1A1 1702/4885
US-20230265058-A1 CARBOXYLIC ACID OR CARBOXYLIC ACID ESTER COMPOUND HAVING FUSED-RING STRUCTURE, METHOD FOR PRODUCING THE SAME, AND USE OF COMPOUND SPG11, HAT1, ASS1 MAPT 1976/4885KDM4E 4186/4885ALDH1A1 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.